Daniel W. Lee, III, MD

Articles by Daniel W. Lee, III, MD

$Daniel W. Lee, III, MD, discusses a case study of polatuzumab vedotin/glofitamab and CD19 CAR T-cell therapy in a child with refractory Burkitt lymphoma.$

Dr Lee on Polatuzumab Vedotin/Glofitamab and CD19 CAR T-Cell Therapy in Pediatric Refractory Burkitt Lymphoma

ByDaniel W. Lee, III, MD

November 6th 2026

Daniel W. Lee, III, MD, discusses a case study of polatuzumab vedotin/glofitamab and CD19 CAR T-cell therapy in a child with refractory Burkitt lymphoma.

Daniel W. Lee, III, MD

Articles by Daniel W. Lee, III, MD

Dr Lee on Polatuzumab Vedotin/Glofitamab and CD19 CAR T-Cell Therapy in Pediatric Refractory Burkitt Lymphoma

Latest Updated Articles

Trending on OncLive

FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC

BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Zanidatamab, CLDN18.2-Directed ADCs, Ivonescimab, and KRAS Inhibitor Data Headline Key GI Cancer Findings From ESMO 2026

LITESPARK-012, XmAb819, and PE-PE Data Headline Key Kidney Cancer Findings From ESMO 2026